

**File no. DCG (I)/Misc.2015(132)**  
**Central Drugs Standard Control Organization**  
**Directorate General of Health Services**  
**Ministry of Health & Family Welfare**  
**O/o Drugs Controller General (I)**

FDA Bhawan, Kotla Road,  
New Delhi-02

Dated: **22 JUL 2015**

**NOTICE**


It is to bring to the notice of all stakeholders that those applicants who have obtained the permission for New Drugs, Clinical Trials or Bio availability/Bioequivalence studies from The Drugs Controller General (I) and not initiated the studies or acted upon the permission for intended purpose for six months after receipt of permission shall intimate such matters to O/o The Drugs Controller General (I) within 15 days failing which necessary action for review of such permissions without further communication would be initiated as per merit under Drugs and Cosmetics Rules.

The requisite information may be sent by letter and email to the respective divisions / email id in the O/o The Drugs Controller General (I).

New Drugs permissions: [newdrug112b@gmail.com](mailto:newdrug112b@gmail.com)

Clinical trials permissions: [cdscog@gmail.com](mailto:cdscog@gmail.com)

Bio availability/Bioequivalence studies NOCs: [babe4export@gmail.com](mailto:babe4export@gmail.com)

  
**(Dr. G.N. Singh)**  
**Drugs Controller General (I)**